MVP — Medical Developments International Share Price
0.000.00%
Last trade - 00:00- AU$50.49m
- AU$37.22m
- AU$32.34m
- 43
- 67
- 38
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 1.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.51 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.57% | ||
| Return on Equity | -23.42% | ||
| Operating Margin | -72.93% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 21.32 | 22.87 | 25.34 | 21.94 | 32.34 | 37.57 | 51.1 | 13.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +288.15 | -63.99 | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medical Developments International Limited is an Australia-based company that delivers emergency medical solutions dedicated to improving patient outcomes in both domestic and international markets. The Company operates in two segments: Pain Management and Respiratory. The Pain Management segment is engaged in the supply of analgesia for acute and procedural pain. The Company manufactures inhaled analgesic, Penthrox (the Green Whistle), at manufacturing facilities at Scoresby and Springvale in Victoria, Australia. Penthrox is sold into domestic and international markets through distribution partnerships and direct in-market capability. The Respiratory segment is a supplier of respiratory products including asthma and chronic obstructive pulmonary disease (COPD) space chambers, peak flow meters, portable nebulizers and silicone face masks. Respiratory supplies into Australia, the United States of America, Europe, and Asia through partnerships with distributors.
Directors
- Gordon Naylor NEC (56)
- Brent MacGregor CEO
- Mark Edwards CFO
- Richard Betts NED
- Robert Johnston NED
- Mary Sontrop NED
- David Williams NED
- Christine Emmanuel NID
- Leon Hoare NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 16th, 2003
- Public Since
- December 15th, 2003
- No. of Shareholders
- 11,527
- No. of Employees
- 68
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 86,305,219
- Address
- 4 Caribbean Drive, Scoresby, MELBOURNE, 3179
- Web
- https://www.medicaldev.com/
- Phone
- +61 395471888
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for MVP
Similar to MVP
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
FAQ
What is the Medical Developments International share price?
As of Today at 19:14 UTC, shares in Medical Developments International are trading at AU$0.59. This share price information is delayed by 15 minutes.
How has the Medical Developments International share price performed this year?
Shares in Medical Developments International last closed at AU$0.59 and the price had moved by -45.58% over the past 365 days. In terms of relative price strength the Medical Developments International share price has underperformed the ASX All Ordinaries Index by -49.31% over the past year.
What are the analyst and broker recommendations for Medical Developments International?
The overall consensus recommendation for Medical Developments International is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Medical Developments International dividend yield?
Medical Developments International does not currently pay a dividend.
Does Medical Developments International pay a dividend?
Medical Developments International does not currently pay a dividend.
When does Medical Developments International next pay dividends?
Medical Developments International does not currently pay a dividend.
How do I buy Medical Developments International shares?
To buy shares in Medical Developments International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medical Developments International?
As of the previous close price of AU$0.59, shares in Medical Developments International had a market capitalisation of AU$50.49m.
Where are Medical Developments International shares listed?
Here are the trading details for Medical Developments International:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MVP
What kind of share is Medical Developments International?
Based on an overall assessment of its quality, value and momentum Medical Developments International is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medical Developments International share price forecast for 2024?
The analyst consensus target price for shares in Medical Developments International is AU$1.60. That is 173.5% above the last closing price of AU$0.59.
Analysts covering Medical Developments International currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.20 for the next financial year.
What is the trend in the Medical Developments International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medical Developments International. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -41.27%.
As of the last closing price of AU$0.59, shares in Medical Developments International were trading -33.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medical Developments International PE Ratio?
The Medical Developments International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medical Developments International?
Medical Developments International's management team is headed by:
- Gordon Naylor - NEC
- Brent MacGregor - CEO
- Mark Edwards - CFO
- Richard Betts - NED
- Robert Johnston - NED
- Mary Sontrop - NED
- David Williams - NED
- Christine Emmanuel - NID
- Leon Hoare - NID